https://nova.newcastle.edu.au/vital/access/ /manager/Index en-au 5 https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:45019 P = 0.968) but did affect major complications (time modeled as quadratic term; odds ratios ranging from 0.20 to 7.91, P_time = 0.001, P_time*time<0.001) and 30-day mortality (odds ratio 1.32, 95% confidence interval: 1.03-1.68, P = 0.030). Conclusion: Surgical delay does not change the need for transfusion of hip fracture patients on DAPT, but it is associated with increased probabilities of major complications and 30-day mortality. Level of Evidence: Therapeutic Level III. See Instructions for Authors for a complete description of levels of evidence.]]> Wed 26 Oct 2022 10:10:24 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:46701 P < 0.0001) and less pharmacologically attributable adverse events (Odds ratio 0.62; 95% confidence interval, 0.46–0.82; P = 0.0007). There was difference between DOACs and conventional VTE prophylaxis regarding mortality, PE, symptomatic deep vein thrombosis, or bleeding events. The results generally support the use of DOACs for VTE prophylaxis after nonelective lower limb fracture surgery, such after hip fracture. The results more strongly support the use of XaIs; however, more evidence is needed to fully assess DOACs' role in clinical practice. Level of Evidence: Therapeutic Level II. See Instructions for Authors for a complete description of levels of evidence.]]> Tue 29 Nov 2022 10:42:17 AEDT ]]>